Related Experiment Video

Updated: May 24, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

Targeting Rho GTPase signaling for cancer therapy

Katerina Mardilovich1, Michael F Olson, Mark Baugh

  • 1Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Future Oncology (London, England)
|February 17, 2012
PubMed

Insights

Rho GTPase signaling pathways are crucial in cancer development. Inhibitors targeting these pathways show promise as cancer therapeutics, driving significant research and development efforts.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Rho GTPases are key regulators of cellular processes implicated in tumor development and progression.
  • Dysregulation of Rho GTPase signaling pathways contributes to cancer pathogenesis.

Purpose of the Study:

  • To review strategies for developing inhibitors of Rho GTPases and downstream signaling kinases.
  • To discuss candidate therapeutic entities targeting Rho GTPase signaling for cancer treatment.

Main Methods:

  • Literature review of basic and clinical studies on Rho GTPase signaling in cancer.
  • Analysis of current strategies for developing targeted inhibitors.
  • Discussion of potential therapeutic agents and their clinical relevance.

Main Results:

  • Evidence supports the role of Rho GTPase signaling in tumor development and progression.
  • Various inhibitors targeting Rho GTPases, their activators, and effectors have been developed.
  • No Rho GTPase-targeted drugs are widely used clinically yet.

Conclusions:

  • Rho GTPase signaling pathways represent promising targets for novel cancer therapies.
  • Continued pharmaceutical research and development are focused on realizing the potential of these targeted drugs.
  • Further clinical investigation is needed to establish the efficacy of Rho GTPase inhibitors in cancer treatment.

More Related Videos

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...